Skip to main content

Table 3 Bleeding and transfusion outcomes

From: Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year follow-up

 Ulinastatin group
(n = 142)
Tranexamic acid group
(n = 143)
Placebo group
(n = 141)
P
Bleeding
 Blood loss within 8 h postoperatively (ml)404.87 ± 253.58380.56 ± 274.3527.73 ± 300.4< 0.001
 Blood loss 9–16 h postoperatively (ml)183.94 ± 151.83165.28 ± 98.02205.57 ± 129.570.004
 Blood loss 17–24 h postoperatively (ml)99.58 ± 94.7591.08 ± 61.64121.03 ± 101.620.034
 Blood loss within 24 h postoperatively (ml)688.39 ± 393.55636.92 ± 368.87854.33 ± 434.03< 0.001
 Blood loss beyond 25 h postoperatively (ml)113.31 ± 108.77111.64 ± 97.73162.34 ± 176.690.096
 Blood loss totality postoperatively (ml)801.7 ± 460.14748.57 ± 409.531016.67 ± 529.08< 0.001
 Major bleeding, n (%)52 (36.62%)42 (29.37%)66 (46.81%)0.010
 Reoperation, n (%)1 (0.7%)0 (0%)6 (4.26%)0.011
Allogenic transfusion
 Red blood cells (unit)2.57 ± 3.152.15 ± 2.73.73 ± 4.210.002
 Plasma (unit)279.61 ± 439.44172.03 ± 298.92382.98 ± 530.490.002
 Platelets (unit)0.01 ± 0.120.03 ± 0.20.06 ± 0.260.160
Patients exposed to allogenic blood products
 Red blood cells, n (%)83 (58.45%)79 (55.24%)98 (69.50%)0.036
 Plasma, n (%)61 (42.96%)49 (34.27%)71 (50.35%)0.023
 Platelets, n (%)2 (1.41%)3 (2.10%)7 (4.96%)0.159
 Any, n (%)97 (68.31%)87 (60.84%)104 (73.76%)0.065
 Ulinastatin vs. Tranexamic acidUlinastatin vs. PlaceboTranexamic acid vs. Placebo
 RD (95%CI) or MD (95%CI)RR (95%CI)P.RD (95%CI) or MD (95%CI)RR (95%CI)PRD (95%CI) or MD (95%CI)RR (95%CI)P
Bleeding
 Blood loss within 8 h postoperatively (ml)24.31 (−37.30,85.91)0.148−122.86 (−195.87,-49.86)< 0.001− 147.17 (− 220.05,-74.30)< 0.001
 Blood loss 9–16 h postoperatively (ml)18.66 (− 11.11,48.44)0.507−21.63 (−55.49,12.22)0.016−40.29 (−74.09,-6.50)0.001
 Blood loss 17–24 h postoperatively (ml)8.49 (−10.13,27.12)0.913−21.45 (−44.58,1.68)0.029−29.94 (−53.03,-6.85)0.020
 Blood loss within 24 h postoperatively (ml)51.46 (−37.47,140.40) 0.257−165.95 (− 262.88,-69.01) < 0.001− 217.41 (− 311.45,-123.37) < 0.001
 Blood loss beyond 25 h postoperatively (ml)1.66 (−22.44,25.77)0.951−49.03 (−83.92,-14.15)0.060−50.70 (−85.52,-15.87)0.062
 Blood loss totality postoperatively (ml)53.13 (−48.42,154.68)0.463− 214.98 (−338.60,-91.36)< 0.001− 268.11 (− 391.51,-144.70)< 0.001
 Major bleeding (person)0.0725 (− 0.0364,0.181)1.25 (0.893,1.74)0.193− 0.102 (− 0.216,0.0124)0.782 (0.592,1.03)0.082− 0.174 (− 0.286,-0.0632)0.628 (0.460,0.855)0.002
 Reoperation (person)0.0070 (− 0.0067,0.0208)3.02 (0.124,73.5)0.315−0.0355 (− 0.0716,0.0005)0.166 (0.0202,1.36)0.055− 0.0426 (− 0.0759,-0.0092)0.0759 (0.0043,1.33)0.012
Allogenic transfusion
 Red blood cells (unit)0.42 (−0.26,1.10)0.330−1.16 (− 2.06,-0.26)0.016−1.58 (− 2.48,-0.69)0.001
 Plasma (unit)107.58 (20.00,195.16)0.052−103.37 (− 217.62,10.88)0.113− 210.95 (− 325.00,-96.90)0.001
 Platelets (unit)− 0.01(− 0.05,0.02)0.656−0.04(− 0.10,0.011)0.088−0.03(− 0.08,0.02)0.195
Patients exposed to allogenic blood products
 Red blood cells (person)0.0321 (−0.0829,0.147)1.058 (0.864,1.30)0.585−0.111 (− 0.222,0.0006)0.841 (0.705,1.00)0.053−0.143 (− 0.254,-0.031)0.795 (0.662,0.955)0.013
 Plasma (person)0.0869 (−0.0257,0.200)1.254 (0.933,1.69)0.132−0.0740 (− 0.190,0.0420)0.853 (0.664,1.10)0.212−0.161 (− 0.274,-0.048)0.681 (0.514,0.900)0.006
 Platelets (person)−0.0069 (− 0.0373,0.0236)0.671 (0.114,3.96)0.658−0.0356 (− 0.0763,0.0052)0.284 (0.0600,1.34)0.088− 0.0287 (− 0.0715,0.0142)0.423 (0.112,1.60)0.190
 Any (person)0.0747 (−0.0360,0.185)1.12 (0.945,1.34)0.187−0.0545 (− 0.160,0.0510)0.926 (0.798,1.08)0.312−0.129 (− 0.237,-0.0212)0.825 (0.700,0.972)0.020